PWM
NBIX icon

Parkworth Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Parkworth Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$251 Hold
2
– – ﹤0.01% 874
2025
Q1 		$221 Hold
2
– – ﹤0.01% 695
2024
Q4 		$273 Buy
+2
New +$247 ﹤0.01% 639

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parkworth Wealth Management's NBIX Position: Q2 2025 in Review

Parkworth Wealth Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2025 at 2 shares worth $251. The position accounts for ﹤0.01% of the portfolio, ranked #874.

Parkworth Wealth Management first reported a position in NBIX in Q4 2024 and has held it in 3 quarters since. The position peaked at $273 in Q4 2024. 585 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • Parkworth Wealth Management held 2 shares of Neurocrine Biosciences worth $251 as of Q2 2025.
  • Parkworth Wealth Management left its Neurocrine Biosciences share count unchanged in Q2 2025.
  • Neurocrine Biosciences made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #874 holding.
  • Parkworth Wealth Management first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 3 quarters since.
  • Parkworth Wealth Management's Neurocrine Biosciences position peaked at $273 in Q4 2024.
  • 585 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.